We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Pharmacological properties of AC-3933, a novel benzodiazepine receptor partial inverse agonist


Want a FREE PDF version of This Article?

Complete the form below and we will email you a PDF version of "Pharmacological properties of AC-3933, a novel benzodiazepine receptor partial inverse agonist"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 

T. Hashimoto, T. Kiyoshi, H. Kohayakawa, Y. Iwamura, N. Yoshida
Neuroscience
October 2013

Abstract: We investigated in this study the pharmacological properties of AC-3933 [5-(3-methoxyphenyl)-3-(5-methyl-1, 2, 4-oxadiazol-3-yl)-1, 6-naphthyridin-2(1H)-one], a novel benzodiazepine receptor (BzR) partial inverse agonist. AC-3933 potently inhibited [3H]-flumazenil binding to rat whole brain membrane with a Ki value of 5.15 ± 0.39 nM and a γ-aminobutyric acid (GABA) ratio of 0.84 ± 0.03. AC-3933 exhibited almost no affinity for the other receptors, transporters and ion channels used in this study. In addition, AC-3933, in the presence of GABA (1 μM), gradually but significantly increased [35S] tert-butylbicyclophosphorothionate ([35S]-TBPS) binding to rat cortical membrane to 117.1% of the control (maximum increase ratio) at 3000 nM. However, this increase reached a plateau at 30 nM with hardly any change at concentration range of 100 nM to 3000 nM (from 115.2% to 117.1%). AC-3933 (0.1-10 μM) significantly enhanced KCl-evoked acetylcholine (ACh) release from rat hippocampal slices in a concentration dependent manner. Moreover, in vivo brain microdialysis showed that intragastric administration of AC-3933 at the dose of 10 mg/kg significantly increased extracellular ACh level in the hippocampus of freely moving rats (AUC0-2 h of ACh level; 288.3% of baseline). These results indicate that AC-3933, a potent and selective BzR inverse agonist with low intrinsic activity, might be useful in the treatment of cognitive disorders associated with degeneration of the cholinergic system.


http://dx.doi.org/10.1016/j.neuroscience.2013.10.031


Advertisement